NeraCare formed a strategic partnership with SkylineDx, which includes an exclusive co-development and licensing agreement for Immunoprint, a proteomic test used to identify early-stage melanoma patients at high risk of relapse and death.
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
